Paper12374678
A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
Fabian CJ and 12 others. Clin Cancer Res, 2002. Cited by 86 papers, by iCite.
Cite this record
ConductScience Library. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Papers, record 12374678. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12374678
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers.
- PubMed
- Publication types
- Clinical Trial, Clinical Trial, Phase II, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Biomarkers, Tumor | Major topic |
| Breast Neoplasms | Major topic |
| Eflornithine | Major topic |
| Enzyme Inhibitors | Major topic |
| Polyamines | Major topic |
| Administration, Oral | |
| Biopsy, Needle | |
| Double-Blind Method | |
| ErbB Receptors | |
| Female | |
| Hormones | |
| Humans | |
| Insulin-Like Growth Factor Binding Protein 3 | |
| Insulin-Like Growth Factor I | |
| Mammography | |
| Middle Aged | |
| Neoplasm Staging | |
| Proliferating Cell Nuclear Antigen | |
| Quality of Life | |
| Tumor Suppressor Protein p53 |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| N01-CN-65124 | NCI NIH HHS | United States | N01CN065124 | PubMed and NIH |
Source NIH RePORTER
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 86 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38943056 | Early detection of breast cancer through the diagnosis of Nipple Aspirate Fluid (NAF). | Clin Proteomics | 2024 | https://conductscience.org/library/papers/38943056 | PubMed |
| 37795002 | Short-Term Biomarker Modulation Study of Dasatinib for Estrogen Receptor-Negative Breast Cancer Chemoprevention. | Eur J Breast Health | 2023 | https://conductscience.org/library/papers/37795002 | PubMed |
| 35620919 | Ototoxicity of Long-Term α-Difluoromethylornithine for Skin Cancer Prevention. | Laryngoscope | 2023 | https://conductscience.org/library/papers/35620919 | PubMed |
| 34067619 | Characterising the Response of Human Breast Cancer Cells to Polyamine Modulation. | Biomolecules | 2021 | https://conductscience.org/library/papers/34067619 | PubMed |
| 33669273 | Polyamine Analog Diethylnorspermidine Restricts Coxsackievirus B3 and Is Overcome by 2A Protease Mutation In Vitro. | Viruses | 2021 | https://conductscience.org/library/papers/33669273 | PubMed |
| 32139506 | Inhibition of the polyamine synthesis enzyme ornithine decarboxylase sensitizes triple-negative breast cancer cells to cytotoxic chemotherapy. | J Biol Chem | 2020 | https://conductscience.org/library/papers/32139506 | PubMed |
| 31052199 | Coxsackievirus B3 Responds to Polyamine Depletion via Enhancement of 2A and 3C Protease Activity. | Viruses | 2019 | https://conductscience.org/library/papers/31052199 | PubMed |
| 31043534 | Polyamine Depletion Inhibits Bunyavirus Infection via Generation of Noninfectious Interfering Virions. | J Virol | 2019 | https://conductscience.org/library/papers/31043534 | PubMed |
| 29533973 | Cellular and Animal Model Studies on the Growth Inhibitory Effects of Polyamine Analogues on Breast Cancer. | Med Sci (Basel) | 2018 | https://conductscience.org/library/papers/29533973 | PubMed |
| 29344009 | Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer. | Clin Proteomics | 2018 | https://conductscience.org/library/papers/29344009 | PubMed |
| 27261491 | Gene Methylation and Cytological Atypia in Random Fine-Needle Aspirates for Assessment of Breast Cancer Risk. | Cancer Prev Res (Phila) | 2016 | https://conductscience.org/library/papers/27261491 | PubMed |
| 25031974 | Random periareolar fine-needle aspiration: the new pap smear of the breast? | J Adv Pract Oncol | 2012 | https://conductscience.org/library/papers/25031974 | PubMed |
| 24166281 | A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. | Breast Cancer Res Treat | 2013 | https://conductscience.org/library/papers/24166281 | PubMed |
| 23221207 | Difluoromethylornithine: the proof is in the polyamines. | Cancer Prev Res (Phila) | 2012 | https://conductscience.org/library/papers/23221207 | PubMed |
| 23181218 | Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. | Front Oncol | 2012 | https://conductscience.org/library/papers/23181218 | PubMed |
| 22924092 | Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer. | Curr Breast Cancer Rep | 2012 | https://conductscience.org/library/papers/22924092 | PubMed |
| 22122766 | DFMO: targeted risk reduction therapy for colorectal neoplasia. | Best Pract Res Clin Gastroenterol | 2011 | https://conductscience.org/library/papers/22122766 | PubMed |
| 21647677 | Pilot and feasibility study: prospective proteomic profiling of mammary epithelial cells from high-risk women provides evidence of activation of pro-survival pathways. | Breast Cancer Res Treat | 2012 | https://conductscience.org/library/papers/21647677 | PubMed |
| 20816506 | Phase II cancer prevention clinical trials. | Semin Oncol | 2010 | https://conductscience.org/library/papers/20816506 | PubMed |
| 20051371 | A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. | Cancer Prev Res (Phila) | 2010 | https://conductscience.org/library/papers/20051371 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| IGF1 | 3479 | PubTator's text mining | https://conductscience.org/library/genes/3479 | NCBI Gene |
| IGFBP3 | 3486 | PubTator's text mining | https://conductscience.org/library/genes/3486 | NCBI Gene |
| ODC1 | 4953 | PubTator's text mining | https://conductscience.org/library/genes/4953 | NCBI Gene |
| PCNA | 5111 | PubTator's text mining | https://conductscience.org/library/genes/5111 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12374678
GET https://conductscience.org/api/papers/v1/12374678/cited_by?page=2